Nurix Therapeutics, Inc. (NRIX) NASDAQ
$23.57 (0.20) (-0.84%)
Market Cap: $1.52B
As of 09/12/24 04:00 PM EDT. Market closed.
Nurix Therapeutics, Inc. (NRIX)
NASDAQ
$23.57
(0.20) (-0.84%)
Market Cap: $1.52B
As of 09/12/24 04:00 PM EDT. Market closed.
Add to Portfolio
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for ... read more
COMPANY PROFILE
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Arthur T. Sands M.D., Ph.D.
Full Time Employees
284
CEO Compensation (Base)
$590,813
CEO Compensation (Total)
$4.36M
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Arthur T. Sands M.D., Ph.D.
Full Time Employees
284
CEO Compensation (Base)
$590,813
CEO Compensation (Total)
$4.36M
URL
Address
1700 Owens Street, CA, San Francisco, 94158.
PRICE CHART FOR NURIX THERAPEUTICS, INC.
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$23.84
Previous Close
$23.77
Days Range
$23.50 - $24.71
52 week range
$4.22 - $26.12
Volume
317,347
Avg. Volume (30 days)
877,341
Market Cap
$1.52B
Dividend Yield
-
P/E
(8.07)
Shares Outstanding
64,411,900
Open
$23.84
Previous Close
$23.77
Days Range
$23.50 - $24.71
52 week range
$4.22 - $26.12
Volume
317,347
Avg. Volume (30 days)
877,341
Market Cap
$1.52B
Dividend Yield
-
P/E
(8.07)
Shares Outstanding
64,411,900
FINANCIAL STATEMENTS FOR NURIX THERAPEUTICS, INC.
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR NURIX THERAPEUTICS, INC.
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Ring Christine | Chief Legal Officer | Sep 03, 2024 | Option Exercise | $4.66 | 9,050 | 42,199 | 33,642 | Sep 03, 2024, 05:33 PM |
| Ring Christine | Chief Legal Officer | Sep 03, 2024 | Sale | $24.94 | 9,050 | 225,736 | 24,792 | Sep 03, 2024, 05:33 PM |
| Ring Christine | Chief Legal Officer | Aug 26, 2024 | Option Exercise | $6.08 | 9,870 | 60,046 | 34,462 | Aug 26, 2024, 06:23 PM |
| Ring Christine | Chief Legal Officer | Aug 26, 2024 | Sale | $25.01 | 9,870 | 246,843 | 24,592 | Aug 26, 2024, 06:23 PM |
| van Houte Hans | Chief Financial Officer | Aug 26, 2024 | Sale | $25.22 | 20,000 | 504,370 | 31,002 | Aug 26, 2024, 05:41 PM |
| van Houte Hans | Chief Financial Officer | Aug 01, 2024 | Sale | $21.45 | 3,477 | 74,576 | 51,102 | Aug 01, 2024, 07:06 PM |
| Ring Christine | Chief Legal Officer | Aug 01, 2024 | Option Exercise | $1.86 | 5,760 | 10,714 | 30,352 | Aug 01, 2024, 07:06 PM |
| Ring Christine | Chief Legal Officer | Aug 01, 2024 | Sale | $21.43 | 5,760 | 123,459 | 24,892 | Aug 01, 2024, 07:06 PM |
| Hansen Gwenn | Chief Scientific Officer | Jul 30, 2024 | Sale | $20.67 | 3,408 | 70,436 | 45,150 | Jul 30, 2024, 07:06 PM |
| Ring Christine | Chief Legal Officer | Jul 30, 2024 | Sale | $20.67 | 2,920 | 60,350 | 24,592 | Jul 30, 2024, 07:06 PM |
| van Houte Hans | Chief Financial Officer | Jul 30, 2024 | Sale | $20.67 | 2,490 | 51,463 | 54,479 | Jul 30, 2024, 07:06 PM |
| Ring Christine | Chief Legal Officer | Jul 01, 2024 | Option Exercise | $1.86 | 5,760 | 10,714 | 25,598 | Jul 01, 2024, 06:35 PM |
| Ring Christine | Chief Legal Officer | Jul 01, 2024 | Sale | $20.81 | 5,760 | 119,837 | 20,639 | Jul 01, 2024, 06:35 PM |
| van Houte Hans | Chief Financial Officer | Jun 20, 2024 | Sale | $20.01 | 20,000 | 400,216 | 48,333 | Jun 20, 2024, 04:58 PM |
| Ring Christine | Chief Legal Officer | Jun 13, 2024 | Option Exercise | $1.86 | 1,864 | 3,467 | 21,702 | Jun 13, 2024, 06:39 PM |
| Ring Christine | Chief Legal Officer | Jun 13, 2024 | Sale | $17.02 | 1,864 | 31,721 | 19,838 | Jun 13, 2024, 06:39 PM |
| Ring Christine | Chief Legal Officer | Jun 12, 2024 | Option Exercise | $1.86 | 1,900 | 3,534 | 21,738 | Jun 12, 2024, 07:30 PM |
| Ring Christine | Chief Legal Officer | Jun 12, 2024 | Sale | $17.01 | 1,900 | 32,319 | 19,838 | Jun 12, 2024, 07:30 PM |
| Ring Christine | Chief Legal Officer | Jun 05, 2024 | Option Exercise | $1.86 | 400 | 744 | 20,238 | Jun 05, 2024, 06:01 PM |
| Ring Christine | Chief Legal Officer | Jun 05, 2024 | Sale | $17.00 | 400 | 6,801 | 19,838 | Jun 05, 2024, 06:01 PM |
| Ring Christine | Chief Legal Officer | Jun 03, 2024 | Option Exercise | $1.86 | 1,596 | 2,969 | 21,434 | Jun 03, 2024, 06:36 PM |
| van Houte Hans | Chief Financial Officer | May 02, 2024 | Sale | $12.83 | 3,499 | 44,878 | 68,333 | May 02, 2024, 06:01 PM |
| van Houte Hans | Chief Financial Officer | Apr 30, 2024 | Sale | $12.04 | 1,387 | 16,703 | 71,832 | Apr 30, 2024, 06:33 PM |
| Hansen Gwenn | Chief Scientific Officer | Apr 30, 2024 | Sale | $12.04 | 2,007 | 24,169 | 39,601 | Apr 30, 2024, 06:33 PM |
| Ring Christine | Chief Legal Officer | Apr 30, 2024 | Sale | $12.04 | 1,513 | 18,220 | 19,838 | Apr 30, 2024, 06:33 PM |
| van Houte Hans | Chief Financial Officer | Feb 16, 2024 | Sale | $10.02 | 6,812 | 68,223 | 68,333 | Feb 16, 2024, 07:20 PM |
| van Houte Hans | Chief Financial Officer | Jan 30, 2024 | Sale | $7.99 | 1,671 | 13,352 | 75,145 | Jan 30, 2024, 06:53 PM |
| Hansen Gwenn | Chief Scientific Officer | Jan 30, 2024 | Sale | $7.99 | 2,334 | 18,649 | 36,402 | Jan 30, 2024, 06:52 PM |
| Ring Christine | Chief Legal Officer | Jan 30, 2024 | Sale | $7.99 | 1,760 | 14,063 | 17,427 | Jan 30, 2024, 06:52 PM |
| van Houte Hans | Chief Financial Officer | Dec 20, 2023 | Sale | $10.00 | 3,541 | 35,421 | 71,930 | Dec 21, 2023, 05:19 PM |
| van Houte Hans | Chief Financial Officer | Dec 19, 2023 | Sale | $10.00 | 10,906 | 109,093 | 75,471 | Dec 20, 2023, 04:55 PM |
| van Houte Hans | Chief Financial Officer | Oct 31, 2023 | Sale | $5.20 | 1,080 | 5,613 | 86,377 | Nov 01, 2023, 04:41 PM |
| Ring Christine | Chief Legal Officer | Oct 31, 2023 | Sale | $5.20 | 1,232 | 6,403 | 15,263 | Nov 01, 2023, 04:40 PM |
| Hansen Gwenn | Chief Scientific Officer | Oct 31, 2023 | Sale | $5.20 | 1,633 | 8,487 | 33,529 | Nov 01, 2023, 04:40 PM |
| van Houte Hans | Chief Financial Officer | Jul 31, 2023 | Sale | $9.65 | 1,245 | 12,020 | 82,571 | Aug 01, 2023, 04:28 PM |
| Ring Christine | General Counsel | Jul 31, 2023 | Sale | $9.65 | 1,420 | 13,710 | 12,544 | Aug 01, 2023, 04:27 PM |
| Hansen Gwenn | Chief Scientific Officer | Jul 31, 2023 | Sale | $9.65 | 1,884 | 18,189 | 29,955 | Aug 01, 2023, 04:26 PM |
| Wolff Stefani | EVP and COO | May 01, 2023 | Sale | $9.88 | 342 | 3,378 | 6,113 | May 02, 2023, 04:33 PM |
| van Houte Hans | Chief Financial Officer | May 01, 2023 | Sale | $9.88 | 721 | 7,121 | 78,930 | May 02, 2023, 04:33 PM |
| Ring Christine | General Counsel | May 01, 2023 | Sale | $9.88 | 682 | 6,736 | 10,040 | May 02, 2023, 04:32 PM |
| Hansen Gwenn | Chief Scientific Officer | May 01, 2023 | Sale | $9.88 | 1,136 | 11,219 | 26,632 | May 02, 2023, 04:31 PM |
| Wolff Stefani | EVP and COO | Jan 30, 2023 | Sale | $11.78 | 424 | 4,995 | 3,940 | Feb 01, 2023, 04:18 PM |
| van Houte Hans | Chief Financial Officer | Jan 30, 2023 | Sale | $11.78 | 924 | 10,884 | 76,765 | Feb 01, 2023, 04:17 PM |
| Ring Christine | General Counsel | Jan 30, 2023 | Sale | $11.78 | 848 | 9,989 | 7,261 | Feb 01, 2023, 04:16 PM |
| Hansen Gwenn | Chief Scientific Officer | Jan 30, 2023 | Sale | $11.78 | 1,412 | 16,633 | 23,009 | Feb 01, 2023, 04:15 PM |
| van Houte Hans | Chief Financial Officer | Oct 31, 2022 | Sale | $12.88 | 739 | 9,519 | 74,803 | Nov 01, 2022, 07:35 PM |
| Ring Christine | General Counsel | Oct 31, 2022 | Sale | $12.88 | 699 | 9,003 | 6,185 | Nov 01, 2022, 07:34 PM |
| Hansen Gwenn | Chief Scientific Officer | Oct 31, 2022 | Sale | $12.88 | 1,165 | 15,006 | 21,214 | Nov 01, 2022, 07:33 PM |
| Wolff Stefani | EVP and COO | Oct 31, 2022 | Sale | $12.88 | 350 | 4,508 | 3,402 | Nov 01, 2022, 07:32 PM |
| Ring Christine | General Counsel | Aug 01, 2022 | Sale | $15.67 | 712 | 11,157 | 4,615 | Aug 02, 2022, 05:50 PM |
| Wolff Stefani | EVP and COO | Aug 01, 2022 | Sale | $15.67 | 356 | 5,579 | 1,238 | Aug 02, 2022, 05:48 PM |
| van Houte Hans | Chief Financial Officer | Aug 01, 2022 | Sale | $15.67 | 752 | 11,784 | 72,656 | Aug 02, 2022, 05:46 PM |
| Hansen Gwenn | Chief Scientific Officer | Aug 01, 2022 | Sale | $15.67 | 1,186 | 18,585 | 19,172 | Aug 02, 2022, 05:45 PM |
| van Houte Hans | Chief Financial Officer | May 31, 2022 | Option Exercise | $0.84 | 68,333 | 57,400 | 70,522 | Jun 01, 2022, 04:57 PM |
| Hansen Gwenn | Chief Scientific Officer | May 02, 2022 | Sale | $11.75 | 1,098 | 12,902 | 17,151 | May 03, 2022, 07:05 PM |
| Wolff Stefani | EVP and COO | May 02, 2022 | Sale | $11.75 | 330 | 3,878 | 632 | May 03, 2022, 07:04 PM |
| van Houte Hans | Chief Financial Officer | May 02, 2022 | Sale | $11.75 | 697 | 8,190 | 2,189 | May 03, 2022, 07:03 PM |
| Ring Christine | General Counsel | May 02, 2022 | Sale | $11.75 | 660 | 7,755 | 3,403 | May 03, 2022, 07:03 PM |
| Ring Christine | General Counsel | Jan 10, 2022 | Option Exercise | $1.86 | 1,200 | 2,232 | 2,486 | Jan 11, 2022, 04:10 PM |
| Ring Christine | General Counsel | Jan 10, 2022 | Sale | $27.14 | 1,200 | 32,568 | 1,286 | Jan 11, 2022, 04:10 PM |
| Ring Christine | General Counsel | Dec 10, 2021 | Option Exercise | $1.86 | 1,200 | 2,232 | 2,486 | Dec 13, 2021, 04:47 PM |
| Ring Christine | General Counsel | Dec 10, 2021 | Sale | $29.04 | 1,200 | 34,848 | 1,286 | Dec 13, 2021, 04:47 PM |
| Hansen Gwenn | Chief Scientific Officer | Dec 01, 2021 | Option Exercise | $7.26 | 400 | 2,904 | 14,597 | Dec 02, 2021, 05:43 PM |
| Hansen Gwenn | Chief Scientific Officer | Dec 01, 2021 | Sale | $29.13 | 400 | 11,652 | 14,197 | Dec 02, 2021, 05:43 PM |
| Ring Christine | General Counsel | Nov 10, 2021 | Option Exercise | $1.86 | 1,200 | 2,232 | 2,486 | Nov 12, 2021, 05:15 PM |
| Ring Christine | General Counsel | Nov 10, 2021 | Sale | $32.38 | 1,200 | 38,856 | 1,286 | Nov 12, 2021, 05:15 PM |
| Hansen Gwenn | Chief Scientific Officer | Nov 01, 2021 | Option Exercise | $7.26 | 400 | 2,904 | 14,597 | Nov 02, 2021, 05:28 PM |
| Hansen Gwenn | Chief Scientific Officer | Nov 01, 2021 | Sale | $33.24 | 400 | 13,296 | 14,197 | Nov 02, 2021, 05:28 PM |
| Ring Christine | General Counsel | Oct 27, 2021 | Option Exercise | $1.86 | 800 | 1,488 | 2,086 | Oct 28, 2021, 07:25 PM |
| Ring Christine | General Counsel | Oct 27, 2021 | Sale | $35.25 | 800 | 28,200 | 1,286 | Oct 28, 2021, 07:25 PM |
| Hansen Gwenn | Chief Scientific Officer | Oct 27, 2021 | Option Exercise | $7.26 | 400 | 2,904 | 14,597 | Oct 28, 2021, 07:23 PM |
| Hansen Gwenn | Chief Scientific Officer | Oct 27, 2021 | Sale | $35.00 | 400 | 14,000 | 14,197 | Oct 28, 2021, 07:23 PM |
| Ring Christine | General Counsel | Oct 11, 2021 | Option Exercise | $1.86 | 1,200 | 2,232 | 2,486 | Oct 12, 2021, 06:43 PM |
| Ring Christine | General Counsel | Oct 11, 2021 | Sale | $27.36 | 1,200 | 32,832 | 1,286 | Oct 12, 2021, 06:43 PM |
| Hansen Gwenn | Chief Scientific Officer | Oct 01, 2021 | Option Exercise | $7.26 | 400 | 2,904 | 14,597 | Oct 04, 2021, 05:16 PM |
| Hansen Gwenn | Chief Scientific Officer | Oct 01, 2021 | Sale | $29.92 | 400 | 11,968 | 14,197 | Oct 04, 2021, 05:16 PM |
| Ring Christine | General Counsel | Sep 10, 2021 | Option Exercise | $1.86 | 2,000 | 3,720 | 3,286 | Sep 13, 2021, 04:07 PM |
| Ring Christine | General Counsel | Sep 10, 2021 | Sale | $35.93 | 2,000 | 71,860 | 2,586 | Sep 13, 2021, 04:07 PM |
| Ring Christine | General Counsel | Sep 07, 2021 | Option Exercise | $1.86 | 3,200 | 5,952 | 4,486 | Sep 08, 2021, 05:08 PM |
| Ring Christine | General Counsel | Sep 07, 2021 | Sale | $35.25 | 3,200 | 112,800 | 1,286 | Sep 08, 2021, 05:08 PM |
| Hansen Gwenn | Chief Scientific Officer | Sep 07, 2021 | Option Exercise | $7.26 | 1,600 | 11,616 | 15,797 | Sep 08, 2021, 05:08 PM |
| Hansen Gwenn | Chief Scientific Officer | Sep 07, 2021 | Sale | $35.00 | 1,600 | 56,000 | 14,197 | Sep 08, 2021, 05:08 PM |
| Hansen Gwenn | Chief Scientific Officer | Sep 01, 2021 | Option Exercise | $7.26 | 400 | 2,904 | 14,597 | Sep 02, 2021, 04:22 PM |
| Hansen Gwenn | Chief Scientific Officer | Sep 01, 2021 | Sale | $32.34 | 400 | 12,936 | 14,197 | Sep 02, 2021, 04:22 PM |
| Ring Christine | General Counsel | Aug 10, 2021 | Option Exercise | $1.86 | 1,200 | 2,232 | 2,005 | Aug 11, 2021, 06:21 PM |
| Ring Christine | General Counsel | Aug 10, 2021 | Sale | $29.87 | 1,200 | 35,845 | 805 | Aug 11, 2021, 06:21 PM |
| Beaurang Pierre | Chief Business Officer | Aug 10, 2021 | Option Exercise | $1.11 | 7,500 | 8,325 | 11,830 | Aug 11, 2021, 06:20 PM |
| Beaurang Pierre | Chief Business Officer | Aug 10, 2021 | Sale | $29.86 | 7,500 | 223,926 | 6,210 | Aug 11, 2021, 06:20 PM |
| Hansen Gwenn | Chief Scientific Officer | Aug 02, 2021 | Option Exercise | $7.26 | 400 | 2,904 | 14,204 | Aug 03, 2021, 05:39 PM |
| Hansen Gwenn | Chief Scientific Officer | Aug 02, 2021 | Sale | $31.21 | 400 | 12,484 | 13,804 | Aug 03, 2021, 05:39 PM |
| Ring Christine | General Counsel | Jul 20, 2021 | Option Exercise | $1.86 | 1,200 | 2,232 | 2,005 | Jul 21, 2021, 05:34 PM |
| Ring Christine | General Counsel | Jul 20, 2021 | Sale | $27.00 | 1,200 | 32,400 | 805 | Jul 21, 2021, 05:34 PM |
| Beaurang Pierre | Chief Business Officer | Jul 12, 2021 | Option Exercise | $1.11 | 7,500 | 8,325 | 11,830 | Jul 12, 2021, 07:36 PM |
| Beaurang Pierre | Chief Business Officer | Jul 12, 2021 | Sale | $23.92 | 7,500 | 179,419 | 4,730 | Jul 12, 2021, 07:36 PM |
| Hansen Gwenn | Chief Scientific Officer | Jul 01, 2021 | Option Exercise | $7.26 | 400 | 2,904 | 14,204 | Jul 02, 2021, 04:03 PM |
| Hansen Gwenn | Chief Scientific Officer | Jul 01, 2021 | Sale | $26.76 | 400 | 10,704 | 13,804 | Jul 02, 2021, 04:03 PM |
| Ring Christine | General Counsel | May 10, 2021 | Option Exercise | $1.86 | 1,200 | 2,232 | 2,005 | May 11, 2021, 07:58 PM |
| Ring Christine | General Counsel | May 10, 2021 | Sale | $27.00 | 1,200 | 32,400 | 805 | May 11, 2021, 07:58 PM |
| Ring Christine | General Counsel | Apr 28, 2021 | Option Exercise | $1.86 | 800 | 1,488 | 1,605 | Apr 29, 2021, 06:05 PM |
| Ring Christine | General Counsel | Apr 28, 2021 | Sale | $35.25 | 800 | 28,200 | 805 | Apr 29, 2021, 06:05 PM |
| Ring Christine | General Counsel | Apr 12, 2021 | Option Exercise | $1.86 | 1,200 | 2,232 | 2,005 | Apr 13, 2021, 05:20 PM |
| Ring Christine | General Counsel | Apr 12, 2021 | Sale | $27.20 | 1,200 | 32,640 | 805 | Apr 13, 2021, 05:20 PM |
| Beaurang Pierre | Chief Business Officer | Apr 12, 2021 | Option Exercise | $1.02 | 7,500 | 7,678 | 11,830 | Apr 13, 2021, 05:19 PM |
| Beaurang Pierre | Chief Business Officer | Apr 12, 2021 | Sale | $27.28 | 7,500 | 204,632 | 7,758 | Apr 13, 2021, 05:19 PM |
| Beaurang Pierre | Chief Business Officer | Mar 25, 2021 | Option Exercise | $0.84 | 4,330 | 3,637 | 4,330 | Mar 25, 2021, 07:23 PM |
| Hansen Gwenn | Chief Scientific Officer | Mar 16, 2021 | Option Exercise | $7.26 | 800 | 5,808 | 14,604 | Mar 16, 2021, 06:50 PM |
| Hansen Gwenn | Chief Scientific Officer | Mar 16, 2021 | Sale | $45.00 | 800 | 36,000 | 13,804 | Mar 16, 2021, 06:50 PM |
| Ring Christine | General Counsel | Mar 10, 2021 | Option Exercise | $1.86 | 2,000 | 3,720 | 2,805 | Mar 11, 2021, 05:35 PM |
| Ring Christine | General Counsel | Mar 10, 2021 | Sale | $41.27 | 2,000 | 82,539 | 1,905 | Mar 11, 2021, 05:35 PM |
| Beaurang Pierre | Chief Business Officer | Mar 08, 2021 | Option Exercise | $0.84 | 7,500 | 6,300 | 7,500 | Mar 09, 2021, 04:04 PM |
| Beaurang Pierre | Chief Business Officer | Mar 08, 2021 | Sale | $37.02 | 7,500 | 277,678 | 4,690 | Mar 09, 2021, 04:04 PM |
| Hansen Gwenn | Chief Scientific Officer | Mar 01, 2021 | Option Exercise | $7.26 | 800 | 5,808 | 14,604 | Mar 02, 2021, 05:29 PM |
| Hansen Gwenn | Chief Scientific Officer | Mar 01, 2021 | Sale | $35.95 | 800 | 28,760 | 13,804 | Mar 02, 2021, 05:29 PM |
| van Houte Hans | Chief Financial Officer | Feb 24, 2021 | Option Exercise | $1.76 | 35,419 | 62,297 | 35,419 | Feb 25, 2021, 04:18 PM |
| van Houte Hans | Chief Financial Officer | Feb 24, 2021 | Sale | $39.90 | 35,419 | 1,413,218 | 0 | Feb 25, 2021, 04:18 PM |
| van Houte Hans | Chief Financial Officer | Feb 22, 2021 | Option Exercise | $1.10 | 5,330 | 5,886 | 5,330 | Feb 23, 2021, 06:04 PM |
| van Houte Hans | Chief Financial Officer | Feb 22, 2021 | Sale | $39.93 | 5,330 | 212,839 | 0 | Feb 23, 2021, 06:04 PM |
| van Houte Hans | Chief Financial Officer | Feb 18, 2021 | Option Exercise | $0.84 | 13,583 | 11,410 | 13,583 | Feb 22, 2021, 04:09 PM |
| van Houte Hans | Chief Financial Officer | Feb 18, 2021 | Sale | $35.46 | 13,583 | 481,621 | 10,443 | Feb 22, 2021, 04:09 PM |
| Ring Christine | General Counsel | Feb 18, 2021 | Option Exercise | $1.86 | 2,000 | 3,720 | 2,000 | Feb 22, 2021, 04:08 PM |
| Ring Christine | General Counsel | Feb 18, 2021 | Sale | $35.88 | 2,000 | 71,750 | 1,600 | Feb 22, 2021, 04:08 PM |
| Hansen Gwenn | Chief Scientific Officer | Feb 18, 2021 | Option Exercise | $7.26 | 800 | 5,808 | 12,800 | Feb 22, 2021, 04:07 PM |
| Hansen Gwenn | Chief Scientific Officer | Feb 18, 2021 | Sale | $36.27 | 800 | 29,018 | 12,200 | Feb 22, 2021, 04:07 PM |
| Beaurang Pierre | Chief Business Officer | Feb 18, 2021 | Option Exercise | $3.68 | 15,000 | 55,275 | 15,000 | Feb 22, 2021, 04:06 PM |
| Beaurang Pierre | Chief Business Officer | Feb 18, 2021 | Sale | $35.49 | 15,000 | 532,352 | 12,353 | Feb 22, 2021, 04:06 PM |
| Hansen Gwenn | Chief Scientific Officer | Nov 30, 2020 | Option Exercise | $0.84 | 12,000 | 10,080 | 12,000 | Dec 01, 2020, 09:32 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Ring Christine | Chief Legal Officer | 09/03/2024 | 42,199 |
| Ring Christine | Chief Legal Officer | 09/03/2024 | 225,736 |
| Ring Christine | Chief Legal Officer | 08/26/2024 | 60,046 |
| Ring Christine | Chief Legal Officer | 08/26/2024 | 246,843 |
| van Houte Hans | Chief Financial Officer | 08/26/2024 | 504,370 |
| van Houte Hans | Chief Financial Officer | 08/01/2024 | 74,576 |
| Ring Christine | Chief Legal Officer | 08/01/2024 | 10,714 |
| Ring Christine | Chief Legal Officer | 08/01/2024 | 123,459 |
| Hansen Gwenn | Chief Scientific Officer | 07/30/2024 | 70,436 |
| Ring Christine | Chief Legal Officer | 07/30/2024 | 60,350 |
| van Houte Hans | Chief Financial Officer | 07/30/2024 | 51,463 |
| Ring Christine | Chief Legal Officer | 07/01/2024 | 10,714 |
| Ring Christine | Chief Legal Officer | 07/01/2024 | 119,837 |
| van Houte Hans | Chief Financial Officer | 06/20/2024 | 400,216 |
| Ring Christine | Chief Legal Officer | 06/13/2024 | 3,467 |
| Ring Christine | Chief Legal Officer | 06/13/2024 | 31,721 |
| Ring Christine | Chief Legal Officer | 06/12/2024 | 3,534 |
| Ring Christine | Chief Legal Officer | 06/12/2024 | 32,319 |
| Ring Christine | Chief Legal Officer | 06/05/2024 | 744 |
| Ring Christine | Chief Legal Officer | 06/05/2024 | 6,801 |
| Ring Christine | Chief Legal Officer | 06/03/2024 | 2,969 |
| van Houte Hans | Chief Financial Officer | 05/02/2024 | 44,878 |
| van Houte Hans | Chief Financial Officer | 04/30/2024 | 16,703 |
| Hansen Gwenn | Chief Scientific Officer | 04/30/2024 | 24,169 |
| Ring Christine | Chief Legal Officer | 04/30/2024 | 18,220 |
| van Houte Hans | Chief Financial Officer | 02/16/2024 | 68,223 |
| van Houte Hans | Chief Financial Officer | 01/30/2024 | 13,352 |
| Hansen Gwenn | Chief Scientific Officer | 01/30/2024 | 18,649 |
| Ring Christine | Chief Legal Officer | 01/30/2024 | 14,063 |
| van Houte Hans | Chief Financial Officer | 12/20/2023 | 35,421 |
| van Houte Hans | Chief Financial Officer | 12/19/2023 | 109,093 |
| van Houte Hans | Chief Financial Officer | 10/31/2023 | 5,613 |
| Ring Christine | Chief Legal Officer | 10/31/2023 | 6,403 |
| Hansen Gwenn | Chief Scientific Officer | 10/31/2023 | 8,487 |
| van Houte Hans | Chief Financial Officer | 07/31/2023 | 12,020 |
| Ring Christine | General Counsel | 07/31/2023 | 13,710 |
| Hansen Gwenn | Chief Scientific Officer | 07/31/2023 | 18,189 |
| Wolff Stefani | EVP and COO | 05/01/2023 | 3,378 |
| van Houte Hans | Chief Financial Officer | 05/01/2023 | 7,121 |
| Ring Christine | General Counsel | 05/01/2023 | 6,736 |
| Hansen Gwenn | Chief Scientific Officer | 05/01/2023 | 11,219 |
| Wolff Stefani | EVP and COO | 01/30/2023 | 4,995 |
| van Houte Hans | Chief Financial Officer | 01/30/2023 | 10,884 |
| Ring Christine | General Counsel | 01/30/2023 | 9,989 |
| Hansen Gwenn | Chief Scientific Officer | 01/30/2023 | 16,633 |
| van Houte Hans | Chief Financial Officer | 10/31/2022 | 9,519 |
| Ring Christine | General Counsel | 10/31/2022 | 9,003 |
| Hansen Gwenn | Chief Scientific Officer | 10/31/2022 | 15,006 |
| Wolff Stefani | EVP and COO | 10/31/2022 | 4,508 |
| Ring Christine | General Counsel | 08/01/2022 | 11,157 |
| Wolff Stefani | EVP and COO | 08/01/2022 | 5,579 |
| van Houte Hans | Chief Financial Officer | 08/01/2022 | 11,784 |
| Hansen Gwenn | Chief Scientific Officer | 08/01/2022 | 18,585 |
| van Houte Hans | Chief Financial Officer | 05/31/2022 | 57,400 |
| Hansen Gwenn | Chief Scientific Officer | 05/02/2022 | 12,902 |
| Wolff Stefani | EVP and COO | 05/02/2022 | 3,878 |
| van Houte Hans | Chief Financial Officer | 05/02/2022 | 8,190 |
| Ring Christine | General Counsel | 05/02/2022 | 7,755 |
| Ring Christine | General Counsel | 01/10/2022 | 2,232 |
| Ring Christine | General Counsel | 01/10/2022 | 32,568 |
| Ring Christine | General Counsel | 12/10/2021 | 2,232 |
| Ring Christine | General Counsel | 12/10/2021 | 34,848 |
| Hansen Gwenn | Chief Scientific Officer | 12/01/2021 | 2,904 |
| Hansen Gwenn | Chief Scientific Officer | 12/01/2021 | 11,652 |
| Ring Christine | General Counsel | 11/10/2021 | 2,232 |
| Ring Christine | General Counsel | 11/10/2021 | 38,856 |
| Hansen Gwenn | Chief Scientific Officer | 11/01/2021 | 2,904 |
| Hansen Gwenn | Chief Scientific Officer | 11/01/2021 | 13,296 |
| Ring Christine | General Counsel | 10/27/2021 | 1,488 |
| Ring Christine | General Counsel | 10/27/2021 | 28,200 |
| Hansen Gwenn | Chief Scientific Officer | 10/27/2021 | 2,904 |
| Hansen Gwenn | Chief Scientific Officer | 10/27/2021 | 14,000 |
| Ring Christine | General Counsel | 10/11/2021 | 2,232 |
| Ring Christine | General Counsel | 10/11/2021 | 32,832 |
| Hansen Gwenn | Chief Scientific Officer | 10/01/2021 | 2,904 |
| Hansen Gwenn | Chief Scientific Officer | 10/01/2021 | 11,968 |
| Ring Christine | General Counsel | 09/10/2021 | 3,720 |
| Ring Christine | General Counsel | 09/10/2021 | 71,860 |
| Ring Christine | General Counsel | 09/07/2021 | 5,952 |
| Ring Christine | General Counsel | 09/07/2021 | 112,800 |
| Hansen Gwenn | Chief Scientific Officer | 09/07/2021 | 11,616 |
| Hansen Gwenn | Chief Scientific Officer | 09/07/2021 | 56,000 |
| Hansen Gwenn | Chief Scientific Officer | 09/01/2021 | 2,904 |
| Hansen Gwenn | Chief Scientific Officer | 09/01/2021 | 12,936 |
| Ring Christine | General Counsel | 08/10/2021 | 2,232 |
| Ring Christine | General Counsel | 08/10/2021 | 35,845 |
| Beaurang Pierre | Chief Business Officer | 08/10/2021 | 8,325 |
| Beaurang Pierre | Chief Business Officer | 08/10/2021 | 223,926 |
| Hansen Gwenn | Chief Scientific Officer | 08/02/2021 | 2,904 |
| Hansen Gwenn | Chief Scientific Officer | 08/02/2021 | 12,484 |
| Ring Christine | General Counsel | 07/20/2021 | 2,232 |
| Ring Christine | General Counsel | 07/20/2021 | 32,400 |
| Beaurang Pierre | Chief Business Officer | 07/12/2021 | 8,325 |
| Beaurang Pierre | Chief Business Officer | 07/12/2021 | 179,419 |
| Hansen Gwenn | Chief Scientific Officer | 07/01/2021 | 2,904 |
| Hansen Gwenn | Chief Scientific Officer | 07/01/2021 | 10,704 |
| Ring Christine | General Counsel | 05/10/2021 | 2,232 |
| Ring Christine | General Counsel | 05/10/2021 | 32,400 |
| Ring Christine | General Counsel | 04/28/2021 | 1,488 |
| Ring Christine | General Counsel | 04/28/2021 | 28,200 |
| Ring Christine | General Counsel | 04/12/2021 | 2,232 |
| Ring Christine | General Counsel | 04/12/2021 | 32,640 |
| Beaurang Pierre | Chief Business Officer | 04/12/2021 | 7,678 |
| Beaurang Pierre | Chief Business Officer | 04/12/2021 | 204,632 |
| Beaurang Pierre | Chief Business Officer | 03/25/2021 | 3,637 |
| Hansen Gwenn | Chief Scientific Officer | 03/16/2021 | 5,808 |
| Hansen Gwenn | Chief Scientific Officer | 03/16/2021 | 36,000 |
| Ring Christine | General Counsel | 03/10/2021 | 3,720 |
| Ring Christine | General Counsel | 03/10/2021 | 82,539 |
| Beaurang Pierre | Chief Business Officer | 03/08/2021 | 6,300 |
| Beaurang Pierre | Chief Business Officer | 03/08/2021 | 277,678 |
| Hansen Gwenn | Chief Scientific Officer | 03/01/2021 | 5,808 |
| Hansen Gwenn | Chief Scientific Officer | 03/01/2021 | 28,760 |
| van Houte Hans | Chief Financial Officer | 02/24/2021 | 62,297 |
| van Houte Hans | Chief Financial Officer | 02/24/2021 | 1,413,218 |
| van Houte Hans | Chief Financial Officer | 02/22/2021 | 5,886 |
| van Houte Hans | Chief Financial Officer | 02/22/2021 | 212,839 |
| van Houte Hans | Chief Financial Officer | 02/18/2021 | 11,410 |
| van Houte Hans | Chief Financial Officer | 02/18/2021 | 481,621 |
| Ring Christine | General Counsel | 02/18/2021 | 3,720 |
| Ring Christine | General Counsel | 02/18/2021 | 71,750 |
| Hansen Gwenn | Chief Scientific Officer | 02/18/2021 | 5,808 |
| Hansen Gwenn | Chief Scientific Officer | 02/18/2021 | 29,018 |
| Beaurang Pierre | Chief Business Officer | 02/18/2021 | 55,275 |
| Beaurang Pierre | Chief Business Officer | 02/18/2021 | 532,352 |
| Hansen Gwenn | Chief Scientific Officer | 11/30/2020 | 10,080 |
Load More Insider Transactions
FUNDS WITH A POSITION IN NURIX THERAPEUTICS, INC.
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BLACKROCK INC. | 6,820,015 | 0.00322% | 48.9% | Other |
| BAKER BROS. ADVISORS LP | 3,882,125 | 1.04% | No change | Other |
| ARK INVESTMENT MANAGEMENT LLC | 2,323,332 | 0.43% | -11.84% | Growth |
| GEODE CAPITAL MANAGEMENT, LLC | 1,321,734 | 0.00242% | 20.12% | Other |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1,283,108 | 0.26% | New | Growth |
| CANDRIAM S.C.A. | 1,164,246 | 0.15% | 30.5% | Other |
| RA CAPITAL MANAGEMENT, L.P. | 650,000 | 0.18% | New | Other |
| RENAISSANCE TECHNOLOGIES LLC | 324,000 | 0.01% | 80.7% | Other |
| FARALLON CAPITAL MANAGEMENT LLC | 108,799 | 0.01% | New | Event Driven, Value |
| DUQUESNE FAMILY OFFICE LLC | 44,200 | 0.03% | No change | Other |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 27,507 | 0.00955% | 66.54% | Other |
| BLACKSTONE INC. | 27,119 | 0.00161% | Exited | Other |
| TUDOR INVESTMENT CORP ET AL | 22,048 | 0.00236% | New | Event Driven, Other |
| AQR CAPITAL MANAGEMENT LLC | 21,296 | 0.00068% | 76.85% | Other |
| ALPINE GLOBAL MANAGEMENT, LLC | 12,681 | 0.05% | New | Event Driven |
| GOTHAM ASSET MANAGEMENT, LLC | 11,872 | 0.00321% | New | Other |
CHANGE IN SHARES OUTSTANDING FOR NURIX THERAPEUTICS, INC.
STOCK BUYBACKS FOR NURIX THERAPEUTICS, INC.
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 05/31/2024
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
02/29/2024
13.61%
1Q
11/30/2023
14.10%
2Q
08/31/2023
14.68%
3Q
05/31/2023
14.96%
4Q
02/28/2023
15.45%
5Q
11/30/2022
15.68%
6Q
08/31/2022
22.63%
7Q
05/31/2022
38.93%
8Q
02/28/2022
39.57%
9Q
11/30/2021
40.02%
10Q
08/31/2021
40.57%
11Q
05/31/2021
42.40%
12Q
02/28/2021
60.86%
13Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR NURIX THERAPEUTICS, INC.
LOADING...